Trials / Completed
CompletedNCT03474562
High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension
Effect of High-Dose Rosuvastatin Combined With Telmisartan or Amlodipine on Glucose Metabolism in Atherosclerotic Cardiovascular Disease (ASCVD) Patients With Impaired Fasting Glucose (IFG) and Hypertension: A Randomized, Open-Label, Parallel, Prospective Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Yuhan Corporation · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effect of high-dose rosuvastatin combined with telmisartan or amlodipine on glucose metabolism in ASCVD patients with impaired fasting glucose and hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Duowell® | Telmisartan/Rosuvastatin 40/20mg (increased to Telmisartan 80mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12) |
| DRUG | Monorova® + Amlopin® | Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12) |
Timeline
- Start date
- 2018-04-03
- Primary completion
- 2019-06-07
- Completion
- 2019-06-07
- First posted
- 2018-03-22
- Last updated
- 2021-06-02
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03474562. Inclusion in this directory is not an endorsement.